The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
In this video, David Swoboda, MD, Tampa General Hospital Cancer Center, Tampa, FL, discusses how evolving myeloid disease classifications and treatment complexity are driving the need for artificial intelligence (AI)-supported decision tools. He highlights early evidence that multi-agent systems can deliver accurate, guideline-based recommendations that outperform general large language models (LLMs). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
